Jason M. Broderick | Authors


Numerical Boost in OS With TAK-700 Misses Threshold for Significance in mHSPC

June 09, 2021

Despite failure to reach the primary end point of statistically significant overall survival benefit, TAK-700 plus androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer may be a valid treatment option for some patients.

Talazoparib Most Likely to Inhibit Response in Men With Heavily Pretreated mCRPC

April 15, 2021

Patients with germline and/or homozygous tumor DNA damage response alterations among male patients with heavily pretreated metastatic castration-resistant prostate cancer were most likely to respond to treatment with the PARP inhibitor talazoparib.

Expert Explores the Current Status of Radium-223 Use in Castration-Resistant Prostate Cancer

March 28, 2021

During a presentation at the 14th Annual New York GU Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Scott T. Tagawa, MD, reviewed important findings related to radium-223 and its use in patients with castration-resistant prostate cancer.

Abiraterone Acetate and Prednisone Plus Apalutamide Reduced Risk of Progression, Death for Patients with mCRPC

February 12, 2021

For patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy, abiraterone acetate and prednisone plus the addition of apalutamide reduced the risk of radiographic progression or death by 30%.